Skip to main content

Typ-2-Diabetes

SGLT-2-Hemmer senkt auch Risiko für akutes Nierenversagen bei Diabetes

This is a preview of subscription content, access via your institution.

1
2

Literatur

  1. 1.

    US Food and Drug Administration (FDA): FDA Drug Safety Communication: FDA Strengthens Kidney Warnings for Diabetes Medicines Cangliflozin (Invokana, Invokamet) and Dapagliflozin, (farxiga, xigduo XR), 2016. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin. Accessed May 10, 2020

  2. 2.

    Cherney DZ, Perkins BA, Soleymanlou N, Majone M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-97

  3. 3.

    Van Raalte DH, Cherney DZI: Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials. Kidney Int 2018; 94: 459-62

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Werner Kleophas.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kleophas, W. SGLT-2-Hemmer senkt auch Risiko für akutes Nierenversagen bei Diabetes. Info Diabetol 15, 10–11 (2021). https://doi.org/10.1007/s15034-021-3693-1

Download citation